US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For M...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SYDNEY, Aug. 24, 2020 /PRNewswire-AsiaNet/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxali...
Authors: LATEST ASIANET NEWS RELEASES